A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Exclusion Criteria

• •1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
• •2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
• •3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
• •4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
• •5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
• •6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
• •7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
• •8. Has history of clinically significant cardiovascular disease as defined in the protocol
• •9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).